Extranuclear coactivator signaling confers insensitivity to tamoxifen

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4123-4130

  Kumar, Rakesh ^a,b   Zhang, Hao ^b   Holm, Caroline ^c   Vadlamudi, Ratna K ^d   Landberg, Goran ^c   Rayala, Suresh K ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LUND UNIVERSITY   (Sweden)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROLINE GLUTAMIC ACID LEUCINE RICH PROTEIN 1; PROTEIN KINASE B; REGULATOR PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST HYPERPLASIA; BREAST TUMOR; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANS-ACTIVATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67449123308     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2347     Document Type: Article

References (30)

1. Cordera F, Jordan VC. Steroid receptors and their role in the biologyand control of breast cancer growth. Semin Oncol 2006;33:631-641 (Pubitemid 44834535)
2. Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006;6:195-216.
3. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007;7:46-53. (Pubitemid 46020846)
4. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007;25:5815-5824
5. Osborne CK. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 1993;47:83-89 (Pubitemid 24040944)
6. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?. J Steroid Biochem Mol Biol 2000;74:255-259 (Pubitemid 32126238)
7. Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 2006;12:1001-7s. (Pubitemid 43259835)
8. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 2003;4:46-56. (Pubitemid 36077256)
9. Iwase H, Omoto Y, Toyama T, et al. Clinical significance of AIB1 expression in human breast cancer. Breast Cancer Res Treat 2003;80:339-345 (Pubitemid 37046758)
10. Vadlamudi RK, Wang R, Mazumdar A, et al. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor α. J Biol Chem 2001;276:38272-38323 (Pubitemid 37384086)
11. Rajhans R, Vadlamudi RK. Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis 2006;23:1-7. (Pubitemid 44576774)
12. Brann DW, Zhang QG, Wang RM, Mahesh VB, Vadlamudi RK. PELP1-A novel estrogen receptor-interacting protein. Mol Cell Endocrinol 2008;290:2-7.
13. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 2004;64:6416-6423 (Pubitemid 39297895)
14. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A 2002;99:14783-14788 (Pubitemid 35334561)
15. Vadlamudi RK, Manavathi B, Balasenthil S, et al. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 2005;65:7724-7732 (Pubitemid 41297247)
16. Dimple C, Nair SS, Rajhans R, et al. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res 2008;68:4902-4909
17. Vadlamudi RK, Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 2007;5:e004.
18. Nair S, Vadlamudi RK. Emerging significance of ER-coregulator PELP1/MNAR in cancer. Histol Histopathol 2007;22:91-96 (Pubitemid 46117094)
19. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA, Kumar R. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activityof estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab 2004;89:6130-6138 (Pubitemid 39628425)
20. Vadlamudi RK, Balasenthil S, Sahin AA, et al. Novel estrogen receptor coactivator PELP1/MNAR gene and ERβ expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol 2005;36:670-675 (Pubitemid 40922574)
21. Rayala SK, Hollander P, Balasenthil S, et al. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem 2006;281:4395-4403 (Pubitemid 43847871)
22. Manavathi B, Nair SS, Wang RA, Kumar R, Vadlamudi RK. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res 2005;65:5571-5577 (Pubitemid 40911157)
23. Bagheri-Yarmand R, Talukder AH, Wang R-A, Vadlamudi RK, Kumar R. Metastasis associated protein 1 deregulation causes inappropriate mammarygland development and tumorigenesis. Development 2004;131:3469-3479 (Pubitemid 39139892)
24. Rose-Hellekant TA, Gilchrist K, Sandgren EP. Strain background alters mammaryg land lesion phenotype in transforming growth factor-α transgenic mice. Am J Pathol 2002;161:1439-1447
25. Ryden L, Jirstrom K, Bendahl P-O, et al. Tumor-specific expression of VEGFR2 is associated with impaired tamoxifen response in premenopausal breast cancer. J Clin Oncol 2005;23:4695-4704
26. Schiff R, Massarweh SA, Shou J, et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 2005;56 Suppl 1:10-20. (Pubitemid 41755686)
27. Kirkegaard T, McGlynn LM, Campbell FM, et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 2007;13:1405-1411 (Pubitemid 46450429)
28. Rajhans R, Nair HB, Nair SS, et al. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Mol Endocrinol 2008;22:649-664
29. Lonard DM, O'Malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007;27:691-700. (Pubitemid 47333229)
30. Nagpal JK, Nair S, Chakravarty D, et al. Growth factor regulation of estrogen receptor coregulator PELP1 functions via protein kinase A pathway. Mol Cancer Res 2008;6:851-861